U.S. markets closed

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7200-0.0700 (-3.91%)
At close: 04:00PM EDT
1.7300 +0.01 (+0.58%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7900
Bid1.7100 x 1000
Ask1.8900 x 1000
Day's Range1.7200 - 1.8600
52 Week Range1.6900 - 8.8200
Avg. Volume262,706
Market Cap66.403M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-2.8050
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TCRR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TCR2 Therapeutics Inc.
    Technical Assessment: Neutral in the Intermediate-TermInterest rates across the entire curve went somewhat parabolic in August. The U.S. Dollar Index continued its very steep ascent. The Federal Reserve is maintaining its hawkish stance based on its latest fed funds targets. As well, the Fed "finally" is getting its quantitative tightening (QT) in gear, which pulls liquidity out of the marketplace. Oh, and stock investors have been losing massive amounts of money. One might believe the economy is falling off a cliff. At least gasoline prices have crashed.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more